Gaviglio Amy, Petritis Kostantinos, Tagi Veronica, Vasco Alessandra, Mauri Alessia, Zuccotti Gianvincenzo, Verduci Elvira, Cereda Cristina, Ferraro Simona
4ES Corporation, Contractor, Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Division of Laboratory Services, Atlanta, GA, USA.
Crit Rev Clin Lab Sci. 2025 Jul 17:1-11. doi: 10.1080/10408363.2025.2527288.
Over the past 60 years, preventative public health screening programs have evolved since their inception and now include newborn screening (NBS) aimed at identifying infants after birth for a number of rare, congenital, inherited diseases. Most of the conditions detected through NBS are autosomal recessive disorders or exhibit X-linked inheritance, meaning that family members of individuals with these conditions have a higher risk for being either affected or obligate heterozygotes. For example, the X-linked adrenoleukodystrophy (X-ALD) in the screening panel identifies affected newborns and asymptomatic relatives through subsequent testing. Thus, NBS becomes a gateway to family-wide prevention, through the application of reverse cascade testing (RCS). In this paper we examined the scenarios where RCS may be appropriate. Accordingly, we have identified a list of criteria assessing whether a NBS disease would benefit from RCS: (1) autosomal recessive or X-linked inheritance; (2) high carrier rates, (3) variable expressivity, (4) mild or late-onset forms; and (5) association with diagnostic delays and recent addition to the screening panel. More than one criterion usually needs to be met for a disease to benefit from RCS. We have identified a list of diseases and highlighted the potential benefits of RCS: X-ALD, Cystic Fibrosis, Sickle Cell Disease, Spinal Muscular Atrophy and Pompe disease. There are additional scenarios within NBS where disease maternal conditions (3-methylcrotonyl-CoA carboxylase deficiency and carnitine uptake deficiency) or nutritional maternal conditions (vitamin B12 deficiency) may cause a screen-positive NBS result. Whenever a maternal nutritional deficiency is a potential reason for a positive NBS, this is indicative of a non-inherited condition that may require treatment in the newborn owing to possible neurological damage and delay in normal growth in newborns with certain secondary deficiencies. For these cases RCS is recommended, as the mother's status may put her at risk for future adverse events (i.e. cardiovascular and musculoskeletal disorders, hepatic involvement, and neurodegeneration). The RCS-NBS strategy discussed in this paper offers a set of criteria against which diseases can be assessed for the potential need for RCS. Implementation of this strategy requires several considerations including educational needs, ethical issues, uptake of testing, logistics and costs for this expanded screening and counseling, and availability of appropriate specialists for ongoing management.
在过去的60年里,预防性公共卫生筛查项目自启动以来不断发展,如今包括新生儿筛查(NBS),旨在在婴儿出生后识别多种罕见的先天性、遗传性疾病。通过NBS检测出的大多数病症是常染色体隐性疾病或表现为X连锁遗传,这意味着患有这些病症的个体的家庭成员成为患者或必然杂合子的风险更高。例如,筛查项目中的X连锁肾上腺脑白质营养不良(X-ALD)通过后续检测来识别患病新生儿和无症状亲属。因此,通过应用反向级联检测(RCS),NBS成为全家庭预防的一个途径。在本文中,我们研究了RCS可能适用的情形。相应地,我们确定了一份评估某种NBS疾病是否能从RCS中获益的标准清单:(1)常染色体隐性或X连锁遗传;(2)高携带率;(3)可变表达性;(4)轻度或迟发性形式;以及(5)与诊断延迟相关且最近被纳入筛查项目。一种疾病通常需要满足不止一条标准才能从RCS中获益。我们确定了一份疾病清单,并强调了RCS的潜在益处:X-ALD、囊性纤维化、镰状细胞病、脊髓性肌萎缩症和庞贝病。在NBS中还存在其他情形,即母亲的疾病状况(3-甲基巴豆酰辅酶A羧化酶缺乏症和肉碱摄取缺乏症)或母亲的营养状况(维生素B12缺乏症)可能导致NBS筛查结果呈阳性。每当母亲的营养缺乏是NBS呈阳性的潜在原因时,这表明这是一种非遗传性状况,由于可能的神经损伤以及某些继发性缺乏的新生儿正常生长发育延迟,可能需要对新生儿进行治疗。对于这些情况,建议采用RCS,因为母亲的状况可能使她面临未来不良事件的风险(即心血管和肌肉骨骼疾病、肝脏受累以及神经退行性变)。本文讨论的RCS-NBS策略提供了一套标准,可据此评估疾病对RCS的潜在需求。实施该策略需要考虑多个方面,包括教育需求、伦理问题、检测的接受度、这种扩大筛查和咨询的后勤保障和成本,以及是否有合适的专家进行持续管理。